دورية أكاديمية
أعرض في EDS

Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits.

التفاصيل البيبلوغرافية
العنوان: Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits.
المؤلفون: Liang X; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Hou X; Department of Physiology, and., Bouhamdan M; Department of Physiology, and., Sun Y; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Song Z; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan, USA., Rajagopalan C; Department of Physiology, and., Jiang H; Department of Physiology, and., Wei HG; Department of Physiology, and., Song J; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Yang D; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Guo Y; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Zhang Y; The Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Mou H; The Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Zhang J; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Chen YE; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Sun F; Department of Physiology, and., Jin JP; Department of Physiology, and., Zhang K; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan, USA., Xu J; Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
المصدر: JCI insight [JCI Insight] 2024 Feb 15; Vol. 9 (6). Date of Electronic Publication: 2024 Feb 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Cystic Fibrosis*/complications , Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/genetics , Liver Diseases*/complications, Animals ; Rabbits ; Glycosides ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/complications
مستخلص: Mutations in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene lead to CF, a life-threating autosomal recessive genetic disease. While recently approved Trikafta dramatically ameliorates CF lung diseases, there is still a lack of effective medicine to treat CF-associated liver disease (CFLD). To address this medical need, we used a recently established CF rabbit model to test whether sotagliflozin, a sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor drug that is approved to treat diabetes, can be repurposed to treat CFLD. Sotagliflozin treatment led to systemic benefits to CF rabbits, evidenced by increased appetite and weight gain as well as prolonged lifespan. For CF liver-related phenotypes, the animals benefited from normalized blood chemistry and bile acid parameters. Furthermore, sotagliflozin alleviated nonalcoholic steatohepatitis-like phenotypes, including liver fibrosis. Intriguingly, sotagliflozin treatment markedly reduced the otherwise elevated endoplasmic reticulum stress responses in the liver and other affected organs of CF rabbits. In summary, our work demonstrates that sotagliflozin attenuates liver disorders in CF rabbits and suggests sotagliflozin as a potential drug to treat CFLD.
References: Pharmacology. 2021;106(11-12):606-615. (PMID: 34515223)
JACC Heart Fail. 2023 Aug;11(8 Pt 1):879-889. (PMID: 37558385)
Ann Intern Med. 2021 Aug;174(8):1065-1072. (PMID: 34152828)
J Lipid Res. 2010 Jan;51(1):23-41. (PMID: 20008121)
Theranostics. 2021 Mar 4;11(9):4502-4515. (PMID: 33754074)
Life Sci. 2021 Dec 1;286:120070. (PMID: 34688695)
Clin Liver Dis. 2019 May;23(2):263-277. (PMID: 30947876)
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F824-F833. (PMID: 29167170)
J Hepatol. 2015 Dec;63(6):1397-404. (PMID: 26220751)
Life Sci. 2020 Sep 1;256:117908. (PMID: 32512011)
J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):421-422. (PMID: 32740535)
Hepatology. 2023 Feb 1;77(2):619-639. (PMID: 35524448)
Science. 1989 Sep 8;245(4922):1066-73. (PMID: 2475911)
Int J Mol Sci. 2020 Nov 14;21(22):. (PMID: 33202578)
J Clin Invest. 2010 Sep;120(9):3149-60. (PMID: 20739752)
Nat Commun. 2023 Feb 8;14(1):693. (PMID: 36755044)
PNAS Nexus. 2022 Dec 23;2(1):pgac306. (PMID: 36712930)
Metabolism. 2019 Sep;98:iii-ix. (PMID: 31301336)
Front Cardiovasc Med. 2021 Feb 10;8:636152. (PMID: 33644138)
Nature. 2008 Jul 24;454(7203):455-62. (PMID: 18650916)
JCI Insight. 2021 Jan 11;6(1):. (PMID: 33232302)
Front Immunol. 2020 Feb 11;10:3154. (PMID: 32117210)
Front Immunol. 2018 Mar 09;9:429. (PMID: 29593714)
Endocrinology. 2014 Mar;155(3):769-82. (PMID: 24424044)
Nat Immunol. 2010 May;11(5):411-8. (PMID: 20351694)
JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. (PMID: 32613148)
Oman Med J. 2019 Nov;34(6):482-489. (PMID: 31745411)
Proc Am Thorac Soc. 2010 Nov;7(6):387-94. (PMID: 21030518)
J Clin Invest. 2004 Jul;114(1):94-103. (PMID: 15232616)
Cell Stem Cell. 2016 Aug 4;19(2):217-231. (PMID: 27320041)
Liver Int. 2023 Apr;43(4):878-887. (PMID: 36797990)
Pediatr Pulmonol. 2018 Nov;53(S3):S30-S50. (PMID: 29999593)
Diabetes Metab Syndr. 2019 May - Jun;13(3):1893-1896. (PMID: 31235111)
J Cyst Fibros. 2007 Apr;6(2):117-23. (PMID: 16829217)
Physiol Rev. 1999 Jan;79(1 Suppl):S215-55. (PMID: 9922383)
J Diabetes Investig. 2020 Jul;11(4):770-782. (PMID: 32196987)
N Engl J Med. 2019 Nov 7;381(19):1863-1865. (PMID: 31670919)
Diabetes Obes Metab. 2020 Jan;22(1):16-29. (PMID: 31407866)
Drugs. 2019 Dec;79(18):1977-1987. (PMID: 31761990)
EMBO J. 2011 Apr 6;30(7):1357-75. (PMID: 21407177)
Cell Mol Gastroenterol Hepatol. 2019;8(2):197-207. (PMID: 31075352)
Clin Exp Hepatol. 2020 Dec;6(4):339-346. (PMID: 33511282)
Front Cardiovasc Med. 2021 Oct 21;8:747620. (PMID: 34746262)
Am J Gastroenterol. 1999 Sep;94(9):2467-74. (PMID: 10484010)
Science. 1992 Aug 21;257(5073):1083-8. (PMID: 1380723)
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-281. (PMID: 30850822)
N Engl J Med. 2021 Jan 14;384(2):117-128. (PMID: 33200892)
Bio Protoc. 2018 Jun 5;8(11):. (PMID: 30009215)
Expert Opin Ther Targets. 2016 Sep;20(9):1109-25. (PMID: 26998950)
Science. 2008 Sep 26;321(5897):1837-41. (PMID: 18818360)
PLoS One. 2014 Mar 07;9(3):e91253. (PMID: 24608905)
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10853-8. (PMID: 19541642)
Respir Med Case Rep. 2021 Nov 10;34:101553. (PMID: 34815934)
JCI Insight. 2018 Oct 4;3(19):. (PMID: 30282831)
Front Genet. 2021 Jan 22;11:627666. (PMID: 33552140)
N Engl J Med. 2021 Jan 14;384(2):129-139. (PMID: 33200891)
J Hepatol. 2013 Jan;58(1):148-54. (PMID: 22902548)
Nat Rev Mol Cell Biol. 2020 Aug;21(8):421-438. (PMID: 32457508)
Endocr Pract. 2022 Feb;28(2):223-230. (PMID: 34606980)
J Pers Med. 2021 Feb 16;11(2):. (PMID: 33669429)
Biomedicines. 2018 May 16;6(2):. (PMID: 29772680)
Drugs. 2019 Jun;79(9):1023-1029. (PMID: 31172412)
J Biol Chem. 2002 Aug 30;277(35):31534-40. (PMID: 12077124)
J Cyst Fibros. 2023 Mar;22(2):256-262. (PMID: 36669962)
EMBO J. 2013 Sep 11;32(18):2477-90. (PMID: 23942232)
Int J Mol Sci. 2019 Oct 22;20(20):. (PMID: 31652578)
Mol Ther Methods Clin Dev. 2021 Nov 24;24:11-19. (PMID: 34977268)
Semin Liver Dis. 2001;21(1):3-16. (PMID: 11296695)
Diab Vasc Dis Res. 2015 Mar;12(2):101-10. (PMID: 25690134)
Eur J Pharmacol. 2019 Oct 5;860:172553. (PMID: 31325433)
Curr Diab Rep. 2022 Jan;22(1):39-52. (PMID: 35113333)
Lab Invest. 2018 Jul;98(7):844-855. (PMID: 29849125)
معلومات مُعتمدة: R01 DK090313 United States DK NIDDK NIH HHS; R01 DK126908 United States DK NIDDK NIH HHS; R01 DK134361 United States DK NIDDK NIH HHS; R01 HL133162 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: Genetic diseases; Hepatology; Therapeutics
المشرفين على المادة: 6B4ZBS263Y ((2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol)
0 (Glycosides)
تواريخ الأحداث: Date Created: 20240215 Date Completed: 20240325 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10972622
DOI: 10.1172/jci.insight.165826
PMID: 38358827
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.165826